Adenovirus infection is a recognized complication following haematopoietic stem cell transplantation. We present a review of our experience of these infections in our transplant cohort over 10 years including 3 patients treated with the novel antiviral brincidofovir.
Five patients received cidofovir alone, one cidofovir then brincidofovir and two brincidofovir alone. 8/10 patients had a decrease in viral load following antivirals and/or reduction in immunosuppression including all on brincidofovir. Three died on treatment.
Conclusions
Disseminated adenovirus infection is uncommon in adult transplant patients and uncertainties remain surrounding effective treatment. In our cohort, brincidofovir has shown promise in treatment of adenoviral infection.
However, randomized controlled studies are required to confirm this impression.
Background
Adenovirus infection is a recognized cause of morbidity and mortality following haematopoietic stem cell transplantation (HSCT) occurring in 5% to 47% of recipients. [1] [2] [3] [4] [5] [6] [7] Infection is often asymptomatic but may result in end-organ disease including colitis, pneumonitis, hepatitis, nephritis, haemorrhagic cystitis, conjunctivitis, encephalitis or multi-site disease following viraemic spread. [8] More commonly seen in the paediatric population [9] , disseminated disease may occur in adult transplant recipients and carries a high mortality of up to 26% [10] . Reported risk factors include T cell depleting conditioning regimes [11] , acute graft versus host disease (GVHD) [9] , unrelated donor allograft [3] and use of alemtuzumab or antithymocyte globulin (ATG) [12] .
Diagnosis of disease is typically made by combining clinical features with detection of viral DNA using polymerase chain reaction (PCR) or identification of viral inclusions on histopathology. Virus detection does not in itself prove significant end-organ disease, but detection at more than one site and increasing viral load, especially in blood, is taken to indicate a high risk.
Management in these circumstances is orientated towards reducing viraemia.
Interventions include reducing immunosuppression and consideration of antivirals; because no antiviral drugs are currently licensed for the treatment of adenoviral disease, such treatments are necessarily investigational. Adoptive T cell immunotherapy holds promise as a treatment [13] although its widespread use is limited by the time-intensive nature of generating virus specific T cells [14] . Intravenous immunoglobulin (IVIG) has also been used in limited cases. [15, 16] The published information on antiviral medications for adenovirus disease, including cidofovir and ribavirin, is limited at present to case series and small non-randomized studies. [17] Cidofovir is an acyclic phosphonate nucleotide analogue whose diphosphate is an inhibitor of the viral DNA polymerase and reduces adenovirus replication in vitro. [18] Its use is limited by side effects including significant nephrotoxicity [19] which can be reduced by pre-hydration and probenecid to decrease tubular secretion of the drug. This introduces a significant management problem in patients undergoing HSCT who often receive nephrotoxic medication for GVHD prophylaxis and antimicrobial, antifungal and antiviral agents.
Brincidofovir (CMX 001, Chimerix Inc, Durham, North Carolina, USA) is an unlicensed orally bioavailable lipid conjugate of cidofovir which demonstrates greater intracellular uptake than cidofovir with a lower propensity for renal accumulation [20, 21] . Brincidofovir has activity against adenovirus in immunosuppressed animal models [22] and is currently under investigation for adenovirus infection in Phase III trials (ClinicalTrials.gov Identifier: NCT02087306).
Here we report 3 cases of disseminated adenovirus infection treated with brincidofovir and relate these to our experience of treating disseminated adenovirus infections in our transplant cohort over 10 years. 
Retrospective review of transplant cohort

Results
Patient characteristics
Over the past 10 years, our unit has carried out 733 HSCTs of which 152 underwent allogeneic myeloablative (MAC), 277 reduced intensity conditioning (RIC) and 312 received autologous haemopoeitic stem cell transplantation (ASCT). Of these 44 had adenovirus DNA detected at one or more sites by PCR. These included 20 females and 24 males with a median age at transplantation of 40 (Range 17-66). Three received autologous stem cell transplantation. Of those receiving allografts, 9 patients were treated with MAC (sibling donor n=5) and 32 with RIC Allo SCT (sibling donor n=18).
Site of infection
The sites most commonly infected were gastrointestinal (GI) tract (n=25), respiratory tract (n=21) and urinary tract (n=6). In addition 1 patient had adenovirus detected in CSF and 3 on eye swabs.
Forty-three of the 44 patients who had adenoviral DNA detected at one organ site also had their blood tested by adenovirus PCR to look for disseminated infection. Seventeen patients had viraemia with a median peak viral load of 3344 (352-11,000,000). Ten patients (23%) including cases 1-3 (detailed below) met criteria for disseminated infection.
Characteristics of patients with disseminated infection
The characteristics of the 10 patients with disseminated infection are summarized in Table 1 . They included 4 male and 6 female patients with a median age of 36.5 (range 19 -59) years, with 8/10 receiving T cell depleted grafts. Median post-transplant time to detection of viraemia was 65 days (range 20-1,140 days). The median peak viral load was 3,133 copies/ml (352-11,000,000) in those who survived and 165,415 copies/ml (41,999-3,000,000) in those who did not. Median duration of viraemia was 14 days (range 7-67) in survivors and 21 days (range 2-103) in those who died. As shown in Table 1 , co-infection with other viruses during the hospital admission was common.
Treatment and outcomes
Five patients received IV cidofovir alone, one cidofovir then brincidofovir (Case 1 described below) and two brincidofovir alone (Cases 2 and 3). Cidofovir doses ranged from 1.5-2mg/kg 3 times a week and brincidofovir doses from 50-100mg twice weekly. Total duration of antiviral treatment ranged from 2 to 63 days.
Among patients given cidofovir, treatment was discontinued in two cases due to nephrotoxicity, in one case was changed to brincidofovir due to lack of efficacy (Case 1), and two patients died with ongoing viraemia.
Information on immunosuppression was available for 9 patients and 6 of these had their immunosuppression reduced. Two patients with disseminated infection only had their immunosuppression reduced and did not receive antivirals. Only two patients received IVIG as part of their treatment. Seven patients became aviraemic (median reduction in viral load of 1.20 log (0.25-4.74log)) and one had a 1.19 log decrease in viral load (case 2). Three died while on treatment (a mortality rate of 30% in those with disseminated infection), although adenovirus disease was only thought to be the primary cause of death in 1 patient (case 4). All those who died had an absolute lymphocyte count of less than 0.25 x10 9 /L at the point of diagnosis.
Case reports
Cases 1-3 from Table 1 who received brincidofovir as part of their treatment are described in detail below.
Case 1
A 59 year old woman underwent a fludarabine, melphalan, alemtuzumab matched unrelated donor peripheral haematopoietic stem cell transplant (MUD Allo SCT) for treatment of acute myeloid leukaemia in second remission.
Cyclosporin A and mycophenolate mofetil were given for GVHD prophylaxis.
On day ten following transplantation, the patient developed severe diarrhoea Following approval for its use on a compassionate basis, brincidofovir was commenced at 100mg twice weekly (at day 44 post transplant). After two doses her viral load in blood had dropped by 2 log10 copies/ml and her respiratory symptoms were improving. However, the diarrhoea persisted for a further 2 weeks. The dose of brincidofovir was reduced to 50mg twice weekly on the grounds that it might be contributing to the diarrhea. However her viral load remained static and given the lack of improvement in her diarrhoeal symptoms, the dose was again increased to 100mg twice weekly. A repeat colonic biopsy at 60 days post-transplant showed epithelial cell apoptosis, a finding which has been documented in both GVHD and adenoviral infection. Adenovirus PCR of this sample was positive. As the viral load continued to decrease in her blood, the brincidofovir dose was again reduced to 50mg twice weekly and her diarrhoea began to settle. After 41 days of brincidofovir treatment, adenovirus became undetectable in blood (<200 copies/ml) and on nasopharyngeal swab.
Of note, she did not develop renal impairment at any stage.
Case 2
A 54 year old woman received sibling allograft with fludarabine and melphalan conditioning for treatment of relapsed IgA myeloma. By day 29 post-transplant, she had developed diarrhea; adenoviral PCR in blood and stool was negative.
Her liver function tests became deranged and she developed mucositis, felt to be consistent with acute GVHD. She was commenced on treatment with methylprednisolone and subsequently with mycophenolate mofetil (MMF) and infliximab. She developed progressive shortness of breath and cough and was found to have a positive adenovirus PCR on a nasopharyngeal sample collected on day 50 post-transplant. She was also viraemic at this point at 4,782 copies/ml rising to a peak of 3,000,000 copies/ml. Adenovirus was also detected in stool. Her steroid dose was reduced and brincidofovir 100mg twice weekly was started at day 52 post transplant with a virological response noted after 8 days of treatment (viral load decreased to 196,201 copies/ml). The contribution of adenovirus to her symptoms is unclear and no symptomatic improvement was seen despite antivirals and GVHD treatment. She continued to deteriorate and died at day 71 post transplantation. Her primary cause of death was felt to be GVHD. Adenovirus was initially detected in blood at day 21 post transplant (6,100 copies/ml) and in stool at day 35. PCR for adenovirus subsequently became strongly positive on blood (peaking at >240000 copies/ml (see Fig 2) .In addition he developed a haemorrhagic cystitis requiring bladder irrigation. Urinary PCR was positive for both adenovirus and BK virus. As his renal function was already abnormal (creatinine clearance 45ml/min), the immunosuppression was reduced and he received treatment on compassionate basis with brincidofovir 100mg twice weekly (started at day 36 post transplant). His symptoms gradually improved and PCR became negative in blood and stool 61 days following treatment initiation (see Fig 2) . Of note the patient also had negative PCR for CMV following 5 weeks treatment with brincidofovir.
Discussion
Viral infections can be life-threatening following allogeneic stem cell transplantation and present major management challenges. Although there have been improvements allowing early identification of adenovirus infection, the optimal management strategy, including antiviral use, remains poorly defined.
There are several reports of the use of brincidofovir for treatment of adenoviral infection in humans including a recent randomized controlled phase II trial. The cases and studies reported in the literature are summarised in Table 2 [20, [25] [26] [27] [28] [29] [30] [31] .
The majority were allogeneic HSCT recipients (both adult and paediatric cases) and many had failed therapy with IV cidofovir prior to initiation of brincidofovir treatment. The dosage varied between 1mg/kg per week and 3mg/kg twice weekly. In this small selection of cases, virological response was often seen in those with viraemia alone, but the reponse was more variable in those with disseminated disease. Recent publications [29, 31] have suggested a potential role for pre-emptive therapy of asymptomatic adenoviraemia to prevent progression to disseminated adenoviral disease in both paediatric and adult transplant populations.
We have here reviewed 10 years of data from adult transplant patients to identify the incidence of adenoviral infection and disease. Amongst our cohort, the incidence of adenoviral infection was 5.9% but disseminated infection was rareseen in 1.24% total transplants. This is comparable to previous data showing an incidence of 3% with attributable mortality for all adenoviral infections of 26% [1] . Known risk factors for infection were reflected in these 10 patients with disseminated infection, the majority of whom received unrelated donor allografts and conditioning with alemtuzumab or ATG.
Viraemia was seen in 16/44 patients of whom 6 did not develop disseminated infection. In our cohort therefore 62.5% of our viraemic patients had disseminated infection of whom 3 died (a mortality rate of 30%). Other small studies have found a higher incidence of viraemia without disseminated disease in adults. [32, 33] This may reflect that our patients were often tested only after detection of virus at another site rather than for routine surveillance.
Of our patients with disseminated infection, 8 were treated with antivirals with 5 surviving. For those on cidofovir, 1/6 was changed to brincidofivir due to lack of efficacy, 2/6 died with viraemia and 2/6 experienced nephrotoxic side effects requiring discontinuation of therapy. Probenecid was used in some cases with no subsequent nephrotoxicity (although these numbers are small). Overall, some virological response occurred in all our patients on brincidofovir and in 3/6 on cidofovir.
Due perhaps in part to the difficulties in diagnosing adenoviral end-organ disease in the context of GVHD and other intercurrent infection, side effects and concerns about efficacy, antivirals were not consistently started when adenovirus was initially detected.
The clinical picture in this cohort was often complicated by acute and chronic GVHD and it is interesting to note that those without documented intercurrent GVHD survived the infection. In contrast, all of those who died had active GVHD and 2/3 were treated with multiple immunosuppressive agents. Case 1 described above appears unusual, with survival despite a very high peak viral load. In other characteristics those who died and those who survived appeared generally similar.
The majority (9/10) of these patients had other concomitant viral infection including CMV reactivation. We note that 3/4 of those without CMV reactivation survived.
As demonstrated by our cases, differentiating between adenoviral disease and other potential aetiologies for symptoms in this setting can be challenging. 
Conclusion
In summary, disseminated adenovirus infection is uncommon in adult transplant recipients but can prove fatal. There remain significant uncertainties surrounding treatment. In our most recent cases, brincidofovir has shown promise in treatment of adenoviral disease without the nephrotoxicity seen with cidofovir and may have a role in preemptive therapy. Due to our screening strategy, we cannot comment on the prevalence of asymptomatic viraemia in our cohort. However given that our disseminated disease cohort reflected known risk factors for adenoviral infection, it may be possible to consider a strategy which screens the most high risk patients and considers pre-emptive therapy.
Randomized controlled studies are required to confirm this impression. 
